



RECEIVED
1012
MAY 28 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Eberhard Nieschlag et al.

Serial No.: 09/764,149

Group Art Unit: 1615

Filed: January 19, 2001

Examiner:
Rachel M. Bennett

For: MALE CONTRACEPTIVE FORMULATION COMPRISING NORETHISTERONE

AMENDMENT AND REPLY

Assistant Commissioner for Patents
Washington, D. C. 20231
Sir:

In response to the Office Action mailed December 21, 2001, kindly amend the above-identified application as follows.

IN THE CLAIMS

✓
Cancel claims 1-56 without prejudice or disclaimer in favor of the following new
claims:

Sub
P1
57. A male contraceptive composition comprising an effective amount of

i) a progestin possessing both androgenic and estrogenic properties; and

ii) testosterone undecanoate,

said testosterone undecanoate formulated for non-oral administration.

58. The composition according to claim 57, wherein the effective amount of testosterone undecanoate corresponds to a dose of between about 800 and 1500 mg for a 6-week administration.